The European Medicines Agency has agreed to review Bristol Myers Squibb’s application requesting approval for the dual immunotherapy regimen Opdivo (nivolumab) and Yervoy (ipilimumab) for untreated, inoperable malignant pleural mesothelioma (MPM). This decision comes after promising data from the Phase 3 CheckMate-743 trial (NCT02899299), in which the immunotherapy combo prolonged patients’ lives from a median of 14.1 months with standard chemo to 18.1 months. “We look forward to working with urgency alongside the EMA towards the goal of…
You must be logged in to read/download the full post.
The post EMA to Review Opdivo-Yervoy Combo for Untreated, Inoperable Mesothelioma appeared first on BioNewsFeeds.